Sermorelin: Evidence, Mechanism, Dosing & Legal Status

Sermorelin (sermorelin acetate; "GRF 1-29") is the synthetic, amidated 1-29 amino-acid fragment of growth hormone-releasing hormone (GHRH) — the bioactive core of the 44-residue parent hormone. Rather than supplying growth hormone from outside, it prompts the pituitary to secrete the body's own GH in physiologic pulses.56 It is heavily marketed as an "anti-aging" peptide; its actual proven uses are narrower and older than that narrative suggests. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Sermorelin has no FDA-approved finished product on the U.S. market; it is available only via pharmacy compounding and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature and historical labeling for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is sermorelin and how does it work?

Sermorelin (CAS 86168-78-7; molecular formula C₁₄₉H₂₄₆N₄₄O₄₂S; molar mass ~3,358 g/mol) is the synthetic amidated 1-29 fragment of endogenous human GHRH — described as "the shortest fully functional fragment of GHRH," retaining essentially full biological activity of the parent hormone.61 Mechanistically it is an agonist at the growth hormone-releasing hormone receptor (GHRHR), a Gs-coupled receptor on anterior-pituitary somatotrophs. Binding raises intracellular cAMP, driving GH gene transcription, synthesis and pulsatile release.56

The defining feature is that it is a secretagogue — it amplifies an endogenous physiologic process rather than introducing a foreign hormone. Crucially, the downstream output stays under normal negative feedback: rising GH and IGF-1 trigger hypothalamic somatostatin, which dampens further secretion, so supraphysiologic IGF-1 and tachyphylaxis are largely avoided — a key contrast with exogenous recombinant GH.52 Sermorelin has a very short plasma half-life of roughly ten to twenty minutes, owing to rapid proteolysis (notably by dipeptidyl peptidase-IV) and renal clearance, yet once-nightly dosing still raises 24-hour integrated GH and serum IGF-1 over days.53 That short half-life is precisely what motivated longer-acting derivatives of this scaffold — CJC-1295 ("modified GRF 1-29") and tesamorelin both descend from it.13

What is the evidence by indication?

Sermorelin's evidence is genuinely human but uneven — strongest for diagnosis and pediatric GH deficiency (the basis of its FDA approvals), weakest for the consumer anti-aging narrative. The table summarizes where each claim stands.

Diagnosis. A single intravenous bolus of sermorelin 1 µg/kg rapidly and relatively specifically stimulates GH release, distinguishing GH-sufficient from GH-deficient children, and produced fewer false positives than some other provocative tests — which supported FDA approval of Geref Diagnostic in 1990.116 Because it acts directly at the pituitary, a normal response cannot exclude GH deficiency of hypothalamic origin, so additional provocative testing is needed in those patients.1

Pediatric GH deficiency. Subcutaneous sermorelin 30 µg/kg/day at bedtime produced significant increases in height velocity sustained over twelve months, with subset data suggesting maintenance through thirty-six months, inducing catch-up growth in the majority of treated children — best in slow-growing, shorter children with delayed bone and height age.1 The important caveat: head-to-head, sermorelin's gains were smaller than once-daily somatropin 30 µg/kg/day, effects on final adult height were never established, and the indication has been largely supplanted by recombinant GH.116

Older adults. In a single-blind, randomized, placebo-controlled trial, 19 men and women aged 55-71 received nightly subcutaneous [Nle27]GHRH(1-29)-NH₂ ~10 µg/kg for sixteen weeks: IGF-1 and IGFBP-3 rose within two weeks, with increased lean body mass (men averaging ~1.26 kg), skin thickness, insulin sensitivity and libido — and no one developed supraphysiologic IGF-1.2 But a separate controlled trial of single nightly GHRH(1-29) injections in healthy elderly men raised 24-hour GH and improved slow-wave sleep while failing to change body weight, BMI, waist-hip ratio, lean body mass or fat mass.3 The takeaway, documented in FDA's own trial registry at ClinicalTrials.gov and the primary literature, is that sermorelin reliably raises the biomarker axis but functional body-composition benefits are inconsistent across the two small, ~30-year-old trials, with no modern large RCT.14

What doses appear in the literature?

Reported strictly as information, not a protocol. For the historical Geref Diagnostic provocative test, the regimen was a single 1 µg/kg intravenous bolus with timed GH sampling.17 For pediatric idiopathic GH deficiency, the historical therapeutic Geref dose was 30 µg/kg subcutaneously once nightly at bedtime, with injection-site rotation; bedtime timing exploits the natural nocturnal GH surge.17 Older-adult research used roughly 10 µg/kg subcutaneously nightly for up to sixteen weeks.2 Historical lyophilized vials were reconstituted with sterile or bacteriostatic diluent and refrigerated; no current FDA-approved finished-product directions exist, and compounded-product instructions are pharmacy-specific.18 Bedtime subcutaneous dosing and the short half-life are designed to mimic physiologic nocturnal GH pulses rather than sustain continuous stimulation.5

How safe is sermorelin?

Sermorelin is generally well tolerated. The most common treatment-related event is a local injection-site reaction (pain, swelling, redness), occurring in about one patient in six; of 350 patients exposed in clinical trials, only three discontinued for injection reactions.7 Other treatment-related events each occurred at under one percent: headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria; the intravenous diagnostic route adds flushing, nausea, vomiting, dysgeusia, pallor and chest tightness.7 A large proportion of patients developed anti-GRF (anti-GHRH) antibodies at least once; titers fluctuated, did not clearly correlate with growth response, and were not linked to a specific adverse-reaction profile.7

The dominant theoretical risk is mechanistic: because GH and IGF-1 are mitogenic and anabolic, there is concern about promoting growth of occult or active malignancy and possibly angiogenesis — so active cancer is treated as a contraindication for GH secretagogues despite the absence of direct sermorelin tumor data.175 The intact negative-feedback axis is the main reason sermorelin is thought less likely than recombinant GH to drive supraphysiologic IGF-1, which the older-adult RCT corroborated.2 Hypersensitivity is an absolute contraindication; pregnancy and lactation are avoided for lack of data; and untreated hypothyroidism blunts the pituitary's GHRH response and should be corrected first.71

What is the FDA and WADA status in 2026?

Sermorelin acetate was FDA-approved twice: Geref Diagnostic (NDA 19-863) in 1990 for evaluating pituitary GH-secretory capacity, and Geref (NDA 20-443) on September 26, 1997 for treating idiopathic GH deficiency in children.166 The manufacturer voluntarily discontinued production in 2008 for commercial reasons — a small market and changing diagnostic practice — and marketing approval was withdrawn effective 2009.4 Critically, in a March 4, 2013 Federal Register determination (Docket FDA-2012-P-1071), the FDA found that Geref injection was not withdrawn for reasons of safety or effectiveness.4 There is no FDA-approved sermorelin finished product on the U.S. market today.

All sermorelin dispensed in 2026 is compounded under pharmacy law. On FDA's interim 503A bulk-substances list it sits in Category 1 ("nominated, under evaluation, no significant safety concern"), where FDA's enforcement-discretion policy applies — unlike Category 2 substances such as BPC-157.1011 This contrasts with the September 2024 removal of five other peptides (AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, Selank) from Category 2, with continued advisory-committee review.12 Off-label prescribing of compounded sermorelin by a licensed physician is generally lawful when medically justified, but it is not approved for weight loss, anti-aging or any adult metabolic indication, and marketing claiming otherwise is misleading.11

For athletes the picture is unambiguous. Sermorelin is prohibited at all times — in and out of competition — under WADA class S2.2.4, "Growth Hormone Releasing Hormones (GHRH) and their analogues," named alongside CJC-1293, CJC-1295 and tesamorelin.89 Detection is analytically challenging — after a single subcutaneous dose the intact peptide is not reliably recovered, though the sermorelin(3-29) metabolite has been identified at roughly thirty minutes.15 Any WADA-tested athlete should treat it as banned.

Bottom line. Sermorelin pairs a real, if modest, human evidence base — diagnostic testing, pediatric GH deficiency, and reliable IGF-1 elevation — with a marketing narrative its data do not support. Graded B for its historical and biomarker-level uses; the anti-aging and performance positioning is preliminary at best. Regulatory facts here are current as of June 2026; compounding categories are fluid and should be re-verified before relying on this status.